KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Consolidated Net Income fell 4476.19% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 5005.01%. This contributed to the annual value of -$248.2 million for FY2024, which is 3607.16% down from last year.
  • Xenon Pharmaceuticals' Consolidated Net Income amounted to -$90.9 million in Q3 2025, which was down 4476.19% from -$84.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Consolidated Net Income registered a high of -$15.4 million during Q3 2021, and its lowest value of -$90.9 million during Q3 2025.
  • Moreover, its 5-year median value for Consolidated Net Income was -$44.7 million (2023), whereas its average is -$46.1 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 1253371.43% in 2021, then plummeted by 1486.81% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$25.6 million in 2021, then plummeted by 46.45% to -$37.4 million in 2022, then decreased by 19.51% to -$44.7 million in 2023, then tumbled by 77.77% to -$79.5 million in 2024, then decreased by 14.28% to -$90.9 million in 2025.
  • Its last three reported values are -$90.9 million in Q3 2025, -$84.7 million for Q2 2025, and -$65.0 million during Q1 2025.